drugset

drugset / Trial / NCT00473928

Safety of Intravitreal POT-4 Therapy for Patients With Neovascular Age-Related Macular Degeneration (AMD)

NCT00473928 ↗

Phase 1 Completed 27 enrolled Potentia Pharmaceuticals, Inc.

Non-randomizedSingle-groupSingle-blindTreatment

Summary

The objective of this study is to provide initial safety and tolerability information of intravitreal POT-4 for treatment of patients with AMD

Timeline

Start: 2007-05
Primary completion: 2010-02
Completion: 2010-02

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	AL-78898A	Unknown	—	Intravitreal

Indications